Xenon-Induced Effects in Relieving Experimental Acute Respiratory Distress Syndrome

被引:0
作者
E. P. Fedorova
M. V. Filonova
A. A. Churin
S. A. Naumov
P. E. Nikiforov
L. A. Sandrikina
D. N. Evtushenko
E. V. Udut
O. S. Popov
S. S. Naumov
T. I. Fomina
V. V. Udut
机构
[1] Tomsk National Research Medical Center,E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
[2] Russian Academy of Sciences,undefined
[3] Siberian State Medical University,undefined
[4] Ministry of Health of the Russian Federation,undefined
[5] Tomsk National Research State University,undefined
来源
Bulletin of Experimental Biology and Medicine | 2023年 / 174卷
关键词
xenon; acute respiratory distress syndrome; acidin-pepsin; E. coli; hemostasis;
D O I
暂无
中图分类号
学科分类号
摘要
The effects of inhalations of an oxygen-xenon (70%/30%) mixture were studied in two models of acute respiratory distress syndrome caused by intratracheal administration of 0.5 mg/kg LPS or 0.04 ml acidin-pepsin (pH 1.2). Inhalation of the oxygen-xenon mixture inhibited the development and reduced the intensity of the inflammatory process in the lung tissue, which was assessed by the dynamics of lung weight and body weight of animals: the therapeutic exposure decreased both parameters. It was found that the thrombogenic stimulus, pathognomonic for the development of acute respiratory distress syndrome, decreased under the effect of oxygen-xenon inhalations, while the level of natural anticoagulant antithrombin III increased.
引用
收藏
页码:605 / 609
页数:4
相关论文
共 30 条
  • [1] Hussain M(2021)Acute Respiratory Distress Syndrome and COVID-19: A Literature Review J. Inflamm. Res. 14 7225-7242
  • [2] Khurram Syed S(2019)The successful treatment of severe aspiration pneumonitis with the combination of hydrocortisone, ascorbic -acid, and thiamine Crit. Care Shock. 22 57-61
  • [3] Fatima M(2010)Pulmonary surfactant pathophysiology: current models and open questions Physiology (Bethesda). 25 132-141
  • [4] Shaukat S(2001)Neutrophil activation and acute lung injury Curr. Opin. Crit. Care. 7 1-7
  • [5] Saadullah M(2020)Fluid administration and monitoring in ARDS: which management? Intensive Care Med. 46 2252-2264
  • [6] Alqahtani AM(undefined)undefined undefined undefined undefined-undefined
  • [7] Alqahtani T(undefined)undefined undefined undefined undefined-undefined
  • [8] Bin Emran T(undefined)undefined undefined undefined undefined-undefined
  • [9] Alamri AH(undefined)undefined undefined undefined undefined-undefined
  • [10] Barkat MQ(undefined)undefined undefined undefined undefined-undefined